Devika Sahu², Monika Sahu¹, Rupesh Pal¹, Minakshi², Priyanshu Dewangan¹, Sobha Sahu¹, Harish Sharma³ and Gyanesh Kumar Sahu¹*

¹Rungta Institute of Pharmaceutical Sciences, Kohka, Kurud, Bhilai, India
²Rungta Institute of Pharmaceutical Sciences and Research, Kohka, Kurud, Bhilai, India
³School of Pharmacy, Anjaneya University, Raipur, India

*Corresponding Author: Dr. Gyanesh Kumar Sahu, Professor and Dean, Rungta Institute of Pharmaceutical Sciences and Research, Kohka, Kurud, Bhilai, India.

Received: December 04, 2024; Published: December 24, 2024

Abstract

Fungal infections pose significant challenges due to their prevalence and resistance to conventional treatments. Miconazole, an azole antifungal agent, is widely recognized for its broad-spectrum activity against dermatophytes, yeasts, and molds. However, con ventional formulations such as creams and ointments often suffer from issues like inconsistent application, poor patient compliance, and reduced efficacy due to limited retention on affected areas.

This review explores the potential of miconazole roll-on gel as a novel, user-friendly formulation for effective antifungal therapy. The roll-on gel format offers benefits such as ease of application, enhanced penetration, and prolonged retention at the infection site, leading to improved therapeutic outcomes. The formulation considerations, including gelling agents, drug release profiles, and stability studies, are discussed in detail.

Moreover, the review examines preclinical and clinical studies evaluating the efficacy, safety, and patient acceptability of the mi conazole roll-on gel compared to conventional formulations. It also highlights the challenges in the development process, such as achieving uniform drug distribution and overcoming formulation stability issues.

The findings indicate that miconazole roll-on gel has the potential to improve antifungal treatment outcomes by addressing limi tations of traditional delivery systems. This review aims to provide insights into its development and to encourage further research in innovative topical drug delivery methods for antifungal therapies

Keywords: Onychomycosis; Clotrimazole; Miconazole

References

1. Amanlou Massoud., et al. "Miconazole gel compared with Zataria multiflora Boiss. gel in the treatment of denture stomatitis”. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives11 (2006): 966-969.
2. Loreto Erico S and Juliana SM Tondolo. "Introductory Chapter: Epidemiology of Invasive Fungal Infection-An Overview”. Fungal Infection (2019).
3. Richardson Malcolm D and David W Warnock. “Fungal infection: diagnosis and management”. John Wiley and Sons, (2012).
4. Sanguinetti M., et al. "Diagnosis and treatment of invasive fungal infections: looking ahead”. Journal of Antimicrobial Chemotherapy 74 (2019): ii27-ii37.
5. Fothergill AW. “Miconazole: a historical perspective”. Expert Review of Anti-infective Therapy2 (2006): 171-175.
6. Piérard GE., et al. "Miconazole, a pharmacological barrier to skin fungal infections”. Expert Opinion on Pharmacotherapy8 (2012): 1187-1194.
7. Ansari S and Prasad R. “Effect of miconazole on the structure and function of plasma membrane of Candida albicans”. FEMS Microbiology Letters1 (1993): 93-98.
8. Shadomy S., et al. "In vitro studies with miconazole and miconazole nitrate”. Journal of Antimicrobial Chemotherapy2 (1977): 147-152.
9. Zhang L W., et al. "Efficacy and safety of miconazole for oral candidiasis: a systematic review and meta‐analysis”. Oral Diseases3 (2016): 185-195.
10. Mohan M., et al. "Management of human keratomycosis with miconazole”. Australian and New Zealand Journal of Ophthalmology3 (1989): 295-297.
11. Capistrano H M., et al. "Brazilian green propolis compared to miconazole gel in the treatment of Candida‐associated denture stomatitis”. Evidence‐Based Complementary and Alternative Medicine 1 (2013): 947980.
12. Regidor PA., et al. "Miconazole for the treatment of vulvovaginal candidiasis. In vitro, in vivo and clinical results. Review of the literature”. Journal of Obstetrics and Gynaecology1 (2023): 2195001.
13. Foster CS. “Miconazole therapy for keratomycosis”. American Journal of Ophthalmology5 (1981): 622-629.
14. Graybill J R. “The future of antifungal therapy”. Clinical Infectious Diseases 22 (1996): S166-S178.
15. Espinel-Ingroff A. “Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009)”. Revista Iberoamericana de Micologia1 (2006): 15-22.
16. Ashley E S D., et al. "Pharmacology of systemic antifungal agents”. Clinical Infectious Diseases 43 (2006): S28-S39.
17. Gupta A K and Tomas E. “New antifungal agents”. Dermatologic Clinics3 (2003): 565-576.
18. Do J., et al. "Antifungal effects of cement mortars with two types of organic antifungal agents”. Cement and Concrete Research2 (2005): 371-376.
19. Goldstein A O and Goldstein BG. “Dermatophyte (tinea) infections”. Walthman, MA: UpToDate, 26-29 (2017).
20. Bseiso E A., et al. "Recent advances in topical formulation carriers of antifungal agents”. Indian Journal of Dermatology, Venereology and Leprology 81 (2015): 457.
21. Pereira PA., et al. "Superficial and cutaneous mycoses, epidemiology, virulence, susceptibility profile to antifungals and their infections: A literature review of the last twenty years”. International Journal of Pharmacy and Biological Sciences1 (2021): 176-187.
22. Schaller M., et al. "Topical antifungal‐corticosteroid combination therapy for the treatment of superficial mycoses: conclusions of an expert panel meeting”. Mycoses6 (2016): 365-373.
23. Santo R D. “Recent patents in antifungal agent discovery”. Expert Opinion on Therapeutic Patents 3 (2008): 275-292.
24. Svetaz LA., et al. "Antifungal drugs combinations: a patent review 2000-2015”. Expert Opinion on Therapeutic Patents 4 (2016): 439-453.
25. Nami S., et al. "Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases”. Biomedicine and Pharmacotherapy 110 (2019): 857-868.
26. Kim J H., et al. "Advances in antifungal development: Discovery of new drugs and drug repurposing”. Pharmaceuticals7 (2022): 787.
27. Nawaz S., et al. "Biocompatible hydrogels for the controlled delivery of anti-hypertensive agent: Development, characterization and in vitro evaluation”. Designed Monomers and Polymers1 (2018): 18-32.
28. Stockman Kenneth E., et al. "Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices”. U.S. Patent 9,393,344, issued July 19 (2016).
29. Gewehr M., et al. "Agricultural mixtures comprising carboxamide compound”. United States patent application US 15/029,908. 2016 Aug 11 (2016).
30. El Mahrab Robert M and Kalia YN. “New developments in topical antifungal therapy”. American Journal of Drug Delivery 4 (2006): 231-247.
31. Imran Mohd., et al. "Mucormycosis medications: a patent review”. Expert Opinion on Therapeutic Patents11 (2021): 1059-1074.
32. Class I P C and USPC A. Patent application title: Coatings and Surface Treatments Having Active Enzymes and Peptides Inventors: C. Steven Mcdaniel (Austin, TX, US) Assignees: REACTIVE SURFACES, LTD (2010).
33. Moriarity Branden., et al. "Tumor infiltrating lymphocytes and methods of therapy”. U.S. Patent 10,912,797, issued February 9 (2021).
34. Salamone Joseph Charles., et al. "Delivery of biologically-active agents using volatile, hydrophobic solvents”. U.S. Patent 8,852,648, issued October 7 (2014).
35. Kreutz T., et al. "Recent patents on permeation enhancers for drug delivery through nails”. Recent patents on drug delivery and formulation 13.3 (2019): 203-218.
36. Svetaz LA., et al. "Antifungal drugs combinations review 2000-2015”. Eaxpert Opinion on Therapeutic patents 26.4 (2016): 439-453.

Citation

Citation: Dr. Gyanesh Kumar Sahu., et al. “Advances in Antifungal Therapies: Miconazole Roll-On Gel as a Convenient Topical Solution"". Acta Scientific Pharmaceutical Sciences 9.1 (2025): 107-113.

Copyright

Copyright: © 2025 Dr. Gyanesh Kumar Sahu., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.